Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: Update of clinical outcome and subgroup analysis

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Ridolfi, Laura ^a   Petrini, Massimiliano ^a   Fiammenghi, Laura ^a   Granato, Anna Maria ^a   Ancarani, Valentina ^a   Pancisi, Elena ^a   Scarpi, Emanuela ^a   Guidoboni, Massimo ^a   Migliori, Giuseppe ^b   Sanna, Stefano ^b   Tauceri, Francesca ^b   Verdecchia, Giorgio Maria ^b   Riccobon, Angela ^a   Ridolfi, Ruggero ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOLOGOUS TUMOR LYSATE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; FOTEMUSTINE; INTERFERON; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; UNCLASSIFIED DRUG; CANCER VACCINE; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOLOGICAL THERAPY; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; GAMMA KNIFE RADIOSURGERY; HUMAN; HYPOTHYROIDISM; LUNG SURGERY; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SOFT TISSUE METASTASIS; SWELLING; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL METASTASIS; VITILIGO; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG THERAPY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; RADIOTHERAPY; SURVIVAL RATE; UTILIZATION REVIEW; VACCINATION;

ADULT; AGED; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DRUG THERAPY; FEMALE; HEMOCYANIN; HUMANS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RADIOTHERAPY; SURVIVAL RATE; TREATMENT OUTCOME; VACCINATION;

EID: 78349261932     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/504979     Document Type: Article

References (52)

1. Baade P., Coory M., Trends in melanoma mortality in Australia: 19502002 and their implications for melanoma control Australian and New Zealand Journal of Public Health 2005 29 4 383 386
2. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002 Ca-A Cancer Journal for Clinicians 2005 55 2 74 108
3. Tsao H., Atkins M., Sober A., Management of cutaneous melanoma New England Journal of Medicine 2004 351 10 998 1012
4. Crosby T., Fish R., Coles B., Mason M. D., Systemic treatments for metastatic cutaneous melanoma Cochrane Database of Systematic Reviews 2000 2 CD001215
5. Lee M. L., Tomsu K., Von Eschen K. B., Duration of survival for disseminated malignant melanoma: results of a meta-analysis Melanoma Research 2000 10 1 81 92
6. Bajetta E., Del Vecchio M., Bernard-Marty C., Vitali M., Buzzoni R., Rixe O., Nova P., Aglione S., Taillibert S., Khayat D., Metastatic melanoma: chemotherapy Seminars in Oncology 2002 29 5 427 445
7. Flaherty K. T., Chemotherapy and targeted therapy combinations in advanced melanoma Clinical Cancer Research 2006 12 7 2366s 2370s
8. Chapman P. B., Einhorn L. H., Meyers M. L., Saxman S., Destro A. N., Panageas K. S., Begg C. B., Agarwala S. S., Schuchter L. M., Ernstoff M. S., Houghton A. N., Kirkwood J. M., Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma Journal of Clinical Oncology 1999 17 9 2745 2751
9. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestles F. O., Enk A., Brcker E.-B., Grabbe S., Rittgen W., Sucker A., Zimpfer-Rechner C., Berger T., Kamarashev J., Burg G., Jonuleit H., Tttenberg A., Becker J. C., Keikavoussi P., Kmpgen E., Schuler G., Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG Annals of Oncology 2006 17 4 563 570
10. Huncharek M., Caubet J. F., McGarry R., Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials Melanoma Research 2001 11 1 75 81
11. Keilholz U., Gore M. E., Biochemotherapy for advanced melanoma Seminars in Oncology 2002 29 5 456 461
12. Pardoll D., Does the immune system see tumors as foreign or self? Annual Review of Immunology 2003 21 807 839
13. Dunn G. P., Old L. J., Schreiber R. D., The immunobiology of cancer immunosurveillance and immunoediting Immunity 2004 21 2 137 148
14. Swann J. B., Smyth M. J., Immune surveillance of tumors Journal of Clinical Investigation 2007 117 5 1137 1146
15. Ferrone S., Whiteside T. L., Tumor Microenvironment and Immune Escape Surgical Oncology Clinics of North America 2007 16 4 755 774
16. Whiteside T. L., The tumor microenvironment and its role in promoting tumor growth Oncogene 2008 27 45 5904 5912
17. Banchereau J., Steinman R. M., Dendritic cells and the control of immunity Nature 1998 392 6673 245 252
18. Lanzavecchia A., Sallusto F., Regulation of T cell immunity by dendritic cells Cell 2001 106 3 263 266
19. Shurin M. R., Dendritic cells presenting tumor antigen Cancer Immunology Immunotherapy 1996 43 3 158 164
20. Rosenberg S. A., Yang J. C., Restifo N. P., Cancer immunotherapy: moving beyond current vaccines Nature Medicine 2004 10 9 909 915
21. Engell-Noerregaard L., Hansen T. H., Andersen M. H., Thor Straten P., Svane I. M., Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters Cancer Immunology, Immunotherapy 2009 58 1 1 14
22. Antonia S. J., Mirza N., Fricke I., Chiappori A., Thompson P., Williams N., Bepler G., Simon G., Janssen W., Lee J.-H., Menander K., Chada S., Gabrilovich D. I., Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer Clinical Cancer Research 2006 12 3 part I 878 887
23. Inogs S., Rodrguez-Calvillo M., Zabalegui N., Lpez-Daz de Cerio A., Villanueva H., Soria E., Surez L., Rodrguez-Caballero A., Pastor F., Garca-Muz R., Panizo C., Prez-Calvo J., Melero I., Rocha E., Orfao A., Bendandi M., Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma Journal of the National Cancer Institute 2006 98 18 1292 1301
24. Gribben J. G., Ryan D. P., Boyajian R., Urban R. G., Hedley M. L., Beach K., Nealon P., Matulonis U., Campos S., Gilligan T. D., Richardson P. G., Marshall B., Neuberg D., Nadler L. M., Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy Clinical Cancer Research 2005 11 12 4430 4436
25. Schlom J., Arlen P. M., Gulley J. L., Cancer vaccines: moving beyond current paradigms Clinical Cancer Research 2007 13 13 3776 3782
26. Ramakrishnan R., Antonia S., Gabrilovich D. I., Combined modality immunotherapy and chemotherapy: a new perspective Cancer Immunology, Immunotherapy 2008 57 10 1523 1529
27. Ridolfi R., Petrini M., Fiammenghi L., Stefanelli M., Ridolfi L., Ballardini M., Migliori G., Riccobon A., Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients Journal of Translational Medicine 2006 4, article 36
28. Hoos A., Parmiani G., Hege K., Sznol M., Loibner H., Eggermont A., Urba W., Blumenstein B., Sacks N., Keilholz U., Nichol G., A clinical development paradigm for cancer vaccines and related biologics Journal of Immunotherapy 2007 30 1 1 15
29. Marubini E., Valsecchi M. G., Barnett V., Analysing survival data from clinical trials and observational studies Statistics in Practice 1995 Chichester, UK John Wiley Sons
30. Middleton M. R., Grob J. J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., Gore M., Aamdal S., Cebon J., Coates A., Dreno B., Henz M., Schadendorf D., Kapp A., Weiss J., Fraass U., Statkevich P., Muller M., Thatcher N., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma Journal of Clinical Oncology 2000 18 1 158 166 (Pubitemid 30036349)
31. Atkins M. B., The treatment of metastatic melanoma with chemotherapy and biologics Current Opinion in Oncology 1997 9 2 205 213
32. Legha S. S., Ring S., Papadopoulos N., Raber M., Benjamin R. S., A phase II trial of taxol in metastatic melanoma Cancer 1990 65 11 2478 2481
33. Bedikian A. Y., Weiss G. R., Legha S. S., Burns H. A. III, Eckardt J. R., Jenkins J., Eton O., Buzaid A. C., Smetzer L., Von Hoff D. D., Benjamin R. S., Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy Journal of Clinical Oncology 1995 13 12 2895 2899
34. Avril M. F., Aamdal S., Grob J. J., Hauschild A., Mohr P., Bonerandi J. J., Weichenthal M., Neuber K., Bieber T., Gilde K., Porta V. G., Fra J., Bonneterre J., Saag P., Kamanabrou D., Pehamberger H., Sufliarsky J., Larriba J. L. G., Scherrer A., Menu Y., Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study Journal of Clinical Oncology 2004 22 6 1118 1125
35. Buzaid A. C., Cisplatin, vinblastine, and dacarbazine versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial Proceedings of the American Society of Clinical Oncology 1993 12 389
36. Atkins M. B., O'Boyle K. R., Sosman J. A., Weiss G. R., Margolin K. A., Ernest M. L., Kappler K., Mier J. W., Sparano J. A., Fisher R. I., Eckardt J. R., Pereira C., Aronson F. R., Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma Journal of Clinical Oncology 1994 12 8 1553 1560
37. Atzpodien J., Lopez Hnninen E., Kirchner H., Franzke A., Korfer A., Volkenandt M., Duensing S., Schomburg A., Chaitchik S., Poliwoda H., Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon- after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen European Journal of Cancer A 1995 31 6 876 881
38. Gibbs P., Iannucci A., Becker M., Allen J., O'Driscoll M., McDowell K., Williams P., Rosse P., Murphy J., Gonzalez R., A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma Melanoma Research 2000 10 2 171 179
39. Legha S. S., Ring S., Bedikian A., Plager C., Eton O., Buzaid A. C., Papadopoulos N., Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon- Annals of Oncology 1996 7 8 827 835
40. Chiarion-Sileni V., Del Bianco P., de Salvo G. L., Lo Re G., Romanini A., Labianca R., Nortilli R., Corgna E., Dalla Palma M., Lo Presti G., Ridolfi R., Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients European Journal of Cancer 2003 39 11 1577 1585
41. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Seipp C. A., Einhorn J. H., White D. E., Steinberg S. M., Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b Journal of Clinical Oncology 1999 17 3 968 975
42. Ives N. J., Stowe R. L., Lorigan P., Wheatley K., Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients Journal of Clinical Oncology 2007 25 34 5426 5434
43. Ridolfi R., Chiarion-Sileni V., Guida M., Romanini A., Labianca R., Freschi A., Lo Re G., Nortilli R., Brugnara S., Vitali P., Nanni O., Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial Journal of Clinical Oncology 2002 20 6 1600 1607
44. Weber J. S., The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies Melanoma Research 2006 16 5 379 383
45. Ridolfi L., Ridolfi R., Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010) Expert Review of Dermatology 2009 4 3 199 210
46. O'Day S. J., Hamid O., Urba W. J., Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies Cancer 2007 110 12 2614 2627
47. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M. C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F. J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.-P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., Andr F., Delaloge S., Tursz T., Kroemer G., Zitvogel L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nature Medicine 2007 13 9 1050 1059
48. Demaria S., Ng B., Devitt M. L., Babb J. S., Kawashima N., Liebes L., Formenti S. C., Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated International Journal of Radiation Oncology Biology Physics 2004 58 3 862 870
49. Demaria S., Bhardwaj N., McBride W. H., Formenti S. C., Combining radiotherapy and immunotherapy: a revived partnership International Journal of Radiation Oncology Biology Physics 2005 63 3 655 666
50. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F., CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative European Journal of Immunology 2004 34 2 336 344
51. Venanzi F. M., Petrini M., Fiammenghi L., Bolli E., Granato A. M., Ridolfi L., Gabrielli F., Barucca A., Concetti A., Ridolfi R., Riccobon A., Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome Cancer Immunology, Immunotherapy 2010 59 1 27 34
52. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G., Immunological aspects of cancer chemotherapy Nature Reviews Immunology 2008 8 1 59 73